To explore the mechanism of Xinnaomaikang granule in the treatment of carotid atherosclerosis based on network pharmacology and molecular docking

This study explores the mechanism of Xinnaomaikang granules in the treatment of carotid atherosclerosis based on network pharmacology. The Chinese medicine components of Xinnaomaiang granules: Salvia miltiorrhiza, Astragalus membranacea, Chrysanthemum, Ligustilian, Gegen, Rhizoma vulgare, Fructus officinalis, and Pinellia farinae, was in the TCMSP for query and screening. Converting the corresponding targets into standard gene names in the Uniprot database to form the Chinese medicine-component data and component-target data. Disease genes using TCMSP, OMIM, Kyoto Encyclopedia of Genes and Genomes (KEGG), DISGENET collection database for diseases as target gene, form a disease-target data; pharmaceutical ingredients by Venny 2.1 software targets and diseases genes targets the intersection of processing. The obtained intersection targets were included in the METASCAP for KEGG pathway enrichment and Gene Ontology pathway enrichment analysis, and then the related network diagram was drawn by Cytoscape_v3.10.0. Xinnaomaikang granules had 89 active ingredients and 298 target genes. And carotid atherosclerosis and atherosclerosis in TCMSP, OMIMDISGENET database collected 2086 target genes, and by analyzing Venny 2.1 both there are altogether 137 intersection target genes, the intersection of target gene mapping KEGG networks, lipid and atherosclerosis pathway, cancer signaling pathways. Fluid shear stress and atherosclerosis, chemical carcinogen-receptor activation pathways, can get the intersection target genes exist corresponding function. The protein-protein interaction networks network diagram of traditional Chinese medicine-component-target-disease was drawn, including the response of cells to lipids, hormones, bacterial-derived molecules, inorganic substances, foreign stimuli, nutrient levels, and defense response regulation. Xinnaomaikang granules have multi-components, multi-pathways and multi-targets to treat carotid atherosclerosis, which provides theoretical basis for clinical application.